News
AOP Orphan Pharmaceuticals presents latest analysis on BESREMi® (Ropeginterferon alfa-2b) in Polycythaemia Vera at the prestigious European Hematology Association (EHA) Annual Meeting 2020
1. 7. 2021Silver Export Award presented to AOP Orphan
9. 4. 2021AOP Orphan reports full validity of arbitral award against PharmaEssentia
25. 3. 2021
From the Concept to the Drug
AOP Orphan headquarters team covers all essential aspects of product development, starting with preclinical research & toxicology, extending to pharmaceutical & clinical development, including regulatory affairs, quality management & pharmacovigilance.
Partnering
Partnering is of key importance for AOP Orphan. It allows further developing AOP Orphan’s rare disease portfolio and enables to approach patients beyond company’s core markets in Europe. Find out more about the cooperation opportunities with AOP Orphan headquarters using the link below.
Join AOP Orphan
In the field of rare diseases the AOP Orphan team develops and investigates therapy options for patients with rare diseases – commitment and appreciation are the essence of our cooperative work.